JPMorgan Chase & Co. Cuts GoodRx (NASDAQ:GDRX) Price Target to $5.00

GoodRx (NASDAQ:GDRX) had its target price lowered by JPMorgan Chase & Co. from $6.00 to $5.00 in a report released on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities analysts have also issued reports about the company. TD Cowen cut their target price on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday. Mizuho lowered their price objective on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $6.00 target price on shares of GoodRx in a report on Monday, August 11th. Weiss Ratings cut GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, UBS Group dropped their price target on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.52.

GoodRx Price Performance

NASDAQ GDRX opened at $3.07 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $1.07 billion, a PE ratio of 34.11, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19. GoodRx has a 12-month low of $2.95 and a 12-month high of $5.81. The company has a 50 day moving average price of $3.92 and a two-hundred day moving average price of $4.24.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. During the same quarter in the prior year, the business posted $0.08 EPS. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. GoodRx has set its FY 2025 guidance at EPS. As a group, equities analysts predict that GoodRx will post 0.13 earnings per share for the current fiscal year.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.53% of the stock is owned by company insiders.

Institutional Trading of GoodRx

A number of hedge funds have recently bought and sold shares of GDRX. Vanguard Group Inc. grew its position in GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after purchasing an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of GoodRx by 4.0% in the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after buying an additional 184,734 shares during the period. Petrus Trust Company LTA grew its position in GoodRx by 7.4% during the first quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company’s stock worth $13,967,000 after buying an additional 216,926 shares in the last quarter. LSV Asset Management increased its stake in GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock valued at $9,960,000 after acquiring an additional 1,973,017 shares during the period. Finally, 8 Knots Management LLC acquired a new position in GoodRx in the 1st quarter valued at approximately $8,106,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.